[Natalizumab as induction therapy in multiple sclerosis].


BACKGROUND Current treatment options for first-line immunotherapy in relapsing-remitting multiple sclerosis (MS) are recombinant interferon-β and glatiramer acetate. However, these therapies are only partially effective and certain patients may fail to respond. For this reason, it is important to elaborate alternative treatment strategies. Induction therapy… (More)
DOI: 10.1016/j.neurol.2013.06.004


1 Figure or Table

Slides referencing similar topics